← All indications
Short Bowel Syndrome
A malabsorption syndrome resulting from extensive operative resection of the SMALL INTESTINE, the absorptive region of the GASTROINTESTINAL TRACT.
Drugs by status
Approved for this indication (4)
Phase 4 trials (6)
Phase 2 trials (14)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (13)
- Merck Serono
- Eli Lilly
- Imagine Institute
- University of Pittsburgh
- Katholieke Universiteit Leuven
- Nanjing University
- Northwestern University
- Stanley Dudrick's Memorial Hospital
- University of Nebraska
- Mayo Clinic
- National Natural Science Foundation of China
- Assistance Publique - Hôpitaux de Paris
- Jinlin University
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (23)
- AbbVie
- Pharmasciences
- Fresenius
- GlaxoSmithKline
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Amarnath, Rathna, M.D.
- University of Pennsylvania
- Emory University
- Pirogov Russian National Research Medical University
- University of Oklahoma
- University of South Carolina
- University of Toronto
- University of Alberta
- University of British Columbia
- University of Calgary
- University of Copenhagen
- Children's Hopsital Boston
- Larix A/S
- GLyPharma Therapeutic
- Imperial College London
- Multispecialty Hospital Stanley Dudrick
- Solumed Centrum Medyczne
- 9 Meters Biopharma, Inc.
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (11)